Shots: The P-III OPTIMUM study results involve assessing of Ponesimod (20 mg) vs Aubagio (teriflunomide, 14mg) in 1,133 patients with relapsing MS for 108wks. at 162 sites across the globe […]readmore
Tags : OPTIMUM
Shots: The P-III OPTIMUM study involves assessing of Ponesimod (20 mg) vs Aubagio (teriflunomide, 14mg) in 1,133 patients with relapsing multiple sclerosis for 108 weeks The study resulted in meeting […]readmore